Tokyo Tape
Sign in
← PeptiDream

Half-year report · Q2

4587.TEDINET S100U7ET
Period2024-01-01 → 2024-06-30
Filed2024-08-09
StandardIFRS
ConsolidatedYes
Data checks12 of 12 passed
Key figures · 48
MetricValuePeriodScopeSource row
Revenue¥36.1bn2024-01-01 → 2024-06-30Cons.Revenue IFRS
Revenue¥28.7bn2023-01-01 → 2023-12-31Cons.Revenue IFRS (5-year summary)
Revenue¥9.4bn2023-01-01 → 2023-06-30Cons.Revenue IFRS
Operating income¥24.6bn2024-01-01 → 2024-06-30Cons.Operating profit loss IFRS
Operating income−¥986m2023-01-01 → 2023-06-30Cons.Operating profit loss IFRS
Profit before tax¥24.7bn2024-01-01 → 2024-06-30Cons.Profit loss before tax IFRS
Profit before tax¥4.4bn2023-01-01 → 2023-12-31Cons.Profit loss before tax IFRS (5-year summary)
Profit before tax−¥1.1bn2023-01-01 → 2023-06-30Cons.Profit loss before tax IFRS
Net income (owners)¥17.9bn2024-01-01 → 2024-06-30Cons.Profit loss attributable to owners of parent IFRS
Net income (owners)¥3.0bn2023-01-01 → 2023-12-31Cons.Profit loss attributable to owners of parent IFRS (5-year summary)
Net income (owners)−¥729m2023-01-01 → 2023-06-30Cons.Profit loss attributable to owners of parent IFRS
Net income¥17.9bn2024-01-01 → 2024-06-30Cons.Profit loss IFRS
Net income¥3.0bn2023-01-01 → 2023-12-31Cons.Profit loss IFRS (5-year summary)
Net income−¥729m2023-01-01 → 2023-06-30Cons.Profit loss IFRS
Total assets¥95.9bnat 2024-06-30Cons.Assets IFRS
Total assets¥69.5bnat 2023-12-31Cons.Assets IFRS
Total assets¥57.7bnat 2023-06-30Cons.Total assets IFRS (5-year summary)
Total liabilities¥37.1bnat 2024-06-30Cons.Liabilities IFRS
Total liabilities¥29.1bnat 2023-12-31Cons.Liabilities IFRS
Net assets / equity¥58.8bnat 2024-06-30Cons.Equity IFRS
Net assets / equity¥40.3bnat 2023-12-31Cons.Equity IFRS
Net assets / equity¥31.0bnat 2023-06-30Cons.Equity IFRS
Net assets / equity¥32.0bnat 2022-12-31dCons.Equity IFRS
Equity (owners)¥58.8bnat 2024-06-30Cons.Equity attributable to owners of parent IFRS
Equity (owners)¥40.3bnat 2023-12-31Cons.Equity attributable to owners of parent IFRS
Equity (owners)¥31.0bnat 2023-06-30Cons.Equity attributable to owners of parent IFRS (5-year summary)
Cash & equivalents¥25.5bnat 2024-06-30Cons.Cash and cash equivalents IFRS
Cash & equivalents¥19.5bnat 2023-12-31Cons.Cash and cash equivalents IFRS
Cash & equivalents¥11.2bnat 2023-06-30Cons.Cash and cash equivalents IFRS
Cash & equivalents¥5.2bnat 2022-12-31dCons.Cash and cash equivalents IFRS
Operating cash flow−¥2.7bn2024-01-01 → 2024-06-30Cons.Net cash provided by used in operating activities IFRS
Operating cash flow¥12.4bn2023-01-01 → 2023-12-31Cons.Cash flows from used in operating activities IFRS (5-year summary)
Operating cash flow¥8.8bn2023-01-01 → 2023-06-30Cons.Net cash provided by used in operating activities IFRS
Investing cash flow¥10.0bn2024-01-01 → 2024-06-30Cons.Net cash provided by used in investing activities IFRS
Investing cash flow¥1.3bn2023-01-01 → 2023-12-31Cons.Cash flows from used in investing activities IFRS (5-year summary)
Investing cash flow−¥798m2023-01-01 → 2023-06-30Cons.Net cash provided by used in investing activities IFRS
Financing cash flow−¥1.5bn2024-01-01 → 2024-06-30Cons.Net cash provided by used in financing activities IFRS
Financing cash flow¥264m2023-01-01 → 2023-12-31Cons.Cash flows from used in financing activities IFRS (5-year summary)
Financing cash flow−¥2.3bn2023-01-01 → 2023-06-30Cons.Net cash provided by used in financing activities IFRS
EPS (basic)¥138.32024-01-01 → 2024-06-30Cons.Basic earnings loss per share IFRS
EPS (basic)¥23.412023-01-01 → 2023-12-31Cons.Basic earnings loss per share IFRS (5-year summary)
EPS (basic)¥-5.622023-01-01 → 2023-06-30Cons.Basic earnings loss per share IFRS
EPS (diluted)¥138.112024-01-01 → 2024-06-30Cons.Diluted earnings loss per share IFRS
EPS (diluted)¥23.382023-01-01 → 2023-12-31Cons.Diluted earnings loss per share IFRS (5-year summary)
EPS (diluted)¥-5.622023-01-01 → 2023-06-30Cons.Diluted earnings loss per share IFRS
Equity ratio61.3%at 2024-06-30Cons.Ratio of owners equity to gross assets IFRS (5-year summary)
Equity ratio58.1%at 2023-12-31Cons.Ratio of owners equity to gross assets IFRS (5-year summary)
Equity ratio53.8%at 2023-06-30Cons.Ratio of owners equity to gross assets IFRS (5-year summary)

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 26
SegmentItemPeriodValue
Reconciling Itemsreconcilingrevenue2024-01-01 → 2024-06-30−¥178m
Reconciling Itemsreconcilingrevenue intersegment2024-01-01 → 2024-06-30−¥178m
jpcrp040300-q2r_E27486-000Drug Discovery And Development Businessreportable segmentrevenue2024-01-01 → 2024-06-30¥28.5bn
jpcrp040300-q2r_E27486-000Drug Discovery And Development Businessreportable segmentrevenue external2024-01-01 → 2024-06-30¥28.5bn
jpcrp040300-q2r_E27486-000Drug Discovery And Development Businessreportable segmentsegment profit2024-01-01 → 2024-06-30¥24.7bn
jpcrp040300-q2r_E27486-000Radiopharmaceuticals Businessreportable segmentrevenue2024-01-01 → 2024-06-30¥7.8bn
jpcrp040300-q2r_E27486-000Radiopharmaceuticals Businessreportable segmentrevenue external2024-01-01 → 2024-06-30¥7.7bn
jpcrp040300-q2r_E27486-000Radiopharmaceuticals Businessreportable segmentrevenue intersegment2024-01-01 → 2024-06-30¥178m
jpcrp040300-q2r_E27486-000Radiopharmaceuticals Businessreportable segmentsegment profit2024-01-01 → 2024-06-30−¥47m
—segment totalrevenue2024-01-01 → 2024-06-30¥36.3bn
—segment totalrevenue external2024-01-01 → 2024-06-30¥36.1bn
—segment totalrevenue intersegment2024-01-01 → 2024-06-30¥178m
—segment totalsegment profit2024-01-01 → 2024-06-30¥24.7bn
Reconciling Itemsreconcilingrevenue2023-01-01 → 2023-06-30−¥30m
Reconciling Itemsreconcilingrevenue intersegment2023-01-01 → 2023-06-30−¥30m
jpcrp040300-q2r_E27486-000Drug Discovery And Development Businessreportable segmentrevenue2023-01-01 → 2023-06-30¥1.5bn
jpcrp040300-q2r_E27486-000Drug Discovery And Development Businessreportable segmentrevenue external2023-01-01 → 2023-06-30¥1.5bn
jpcrp040300-q2r_E27486-000Drug Discovery And Development Businessreportable segmentsegment profit2023-01-01 → 2023-06-30−¥1.2bn
jpcrp040300-q2r_E27486-000Radiopharmaceuticals Businessreportable segmentrevenue2023-01-01 → 2023-06-30¥8.0bn
jpcrp040300-q2r_E27486-000Radiopharmaceuticals Businessreportable segmentrevenue external2023-01-01 → 2023-06-30¥8.0bn
jpcrp040300-q2r_E27486-000Radiopharmaceuticals Businessreportable segmentrevenue intersegment2023-01-01 → 2023-06-30¥30m
jpcrp040300-q2r_E27486-000Radiopharmaceuticals Businessreportable segmentsegment profit2023-01-01 → 2023-06-30¥228m
—segment totalrevenue2023-01-01 → 2023-06-30¥9.5bn
—segment totalrevenue external2023-01-01 → 2023-06-30¥9.4bn
—segment totalrevenue intersegment2023-01-01 → 2023-06-30¥30m
—segment totalsegment profit2023-01-01 → 2023-06-30−¥941m

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 586
ItemContextValueUnit
Retirement benefit liability ncl IFRSPrior1YearInstant97647000JPY
Retirement benefit liability ncl IFRSCurrentQuarterInstant95046000JPY
Provisions ncl IFRSPrior1YearInstant56120000JPY
Provisions ncl IFRSCurrentQuarterInstant59157000JPY
Non current labilities IFRSPrior1YearInstant20497214000JPY
Non current labilities IFRSCurrentQuarterInstant18860727000JPY
Liabilities IFRSPrior1YearInstant29114303000JPY
Liabilities IFRSCurrentQuarterInstant37110606000JPY
Share capital IFRSPrior1YearInstant3956738000JPY
Share capital IFRSCurrentQuarterInstant3956738000JPY
Capital surplus IFRSPrior1YearInstant4550372000JPY
Capital surplus IFRSCurrentQuarterInstant4566129000JPY
Treasury shares IFRSPrior1YearInstant-1085546000JPY
Treasury shares IFRSCurrentQuarterInstant-1075128000JPY
Retained earnings IFRSPrior1YearInstant27804689000JPY
Retained earnings IFRSCurrentQuarterInstant52269245000JPY
Other components of equity IFRSPrior1YearInstant5123456000JPY
Other components of equity IFRSCurrentQuarterInstant-946349000JPY
Equity attributable to owners of parent IFRSPrior1YearInstant40349709000JPY
Equity attributable to owners of parent IFRSCurrentQuarterInstant58770634000JPY
Equity IFRSPrior1YearInstant40349709000JPY
Equity IFRSCurrentQuarterInstant58770634000JPY
Liabilities and equity IFRSPrior1YearInstant69464013000JPY
Liabilities and equity IFRSCurrentQuarterInstant95881241000JPY
Revenue IFRSPrior1YTDDuration9426049000JPY
Revenue IFRSCurrentYTDDuration36133625000JPY
Cost of sales IFRSPrior1YTDDuration5464694000JPY
Cost of sales IFRSCurrentYTDDuration6172764000JPY
Gross profit IFRSPrior1YTDDuration3961355000JPY
Gross profit IFRSCurrentYTDDuration29960861000JPY
Selling general and administrative expenses IFRSPrior1YTDDuration3429071000JPY
Selling general and administrative expenses IFRSCurrentYTDDuration3804852000JPY
Research and development expenses IFRSPrior1YTDDuration1506241000JPY
Research and development expenses IFRSCurrentYTDDuration1471800000JPY
Other income IFRSPrior1YTDDuration3939000JPY
Other income IFRSCurrentYTDDuration29000JPY
Other expenses IFRSPrior1YTDDuration16079000JPY
Other expenses IFRSCurrentYTDDuration34954000JPY
Operating profit loss IFRSPrior1YTDDuration-986098000JPY
Operating profit loss IFRSCurrentYTDDuration24649283000JPY
Finance income IFRSPrior1YTDDuration103153000JPY
Finance income IFRSCurrentYTDDuration335214000JPY
Finance costs IFRSPrior1YTDDuration124756000JPY
Finance costs IFRSCurrentYTDDuration136342000JPY
Share of profit loss of investments accounted for using equity method IFRSPrior1YTDDuration-103231000JPY
Share of profit loss of investments accounted for using equity method IFRSCurrentYTDDuration-105927000JPY
Profit loss before tax IFRSPrior1YTDDuration-1110932000JPY
Profit loss before tax IFRSCurrentYTDDuration24742228000JPY
Income tax expense IFRSPrior1YTDDuration-381918000JPY
Income tax expense IFRSCurrentYTDDuration6816926000JPY

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 12 of 12 passed
balance sheet identityconsolidated 2023-12-31pass rounding
balance sheet identityconsolidated 2024-06-30pass rounding
dei present pass
period resolution pass
statement vs summary · net income attributable to parentconsolidated 2023-01-01/2023-06-30pass
statement vs summary · net income attributable to parentconsolidated 2024-01-01/2024-06-30pass
statement vs summary · operating cash flowconsolidated 2023-01-01/2023-06-30pass
statement vs summary · operating cash flowconsolidated 2024-01-01/2024-06-30pass
statement vs summary · revenueconsolidated 2023-01-01/2023-06-30pass
statement vs summary · revenueconsolidated 2024-01-01/2024-06-30pass
statement vs summary · total assetsconsolidated 2023-12-31pass
statement vs summary · total assetsconsolidated 2024-06-30pass